A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure

2015203 citationsJournal Articlebronze Open Access

Authors

Emerson C. Perin · Monash University

Kenneth M. Borow · Bryn Mawr College

Guilherme V. Silva · Swedish Medical Center

Anthony N. DeMaria · Bryn Mawr College

Oscar C. Marroquin · University of California, San Diego

Paul P. Huang · Minneapolis Heart Institute Foundation

Jay H. Traverse

Abstract

Transendocardial injections of allogeneic MPCs were feasible and safe in chronic HF patients. High-dose allogeneic MPCs may provide benefits in this population.

Topics & Keywords

Mechanical Circulatory Support Devices Mesenchymal stem cell research Cardiac Structural Anomalies and Repair

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Circulation Research

Volume 117, Issue 6, pp. 576-584

DOI: 10.1161/circresaha.115.306332

Field-Weighted Citation Impact: 16.52